ETHICS APPROVAL FOR PAPERS SUBMITTED TO “MUSCLES, LIGAMENTS AND TENDONS JOURNAL”

JOURNAL POLICIES

Meeting the internationally accepted ethical standards of all articles published on “Muscles, Ligaments and Tendons Journal” (hereafter called “MLTJ”) is a primary aim of the Editors. MLTJ considers the ethical aspects of submitted works involving human or animal subjects.

The Editors, along with the reviewers, will judge the design of the study and how it was conducted, to verify if the used methods are morally justifiable. If the previous subjects find out an unethical conduction of the study, it will be rejected although hypothetical relevant results.

We require that authors submit a paper providing:

the name of the approving committee;
approval number or code protocol;
the date.

This kind of information must be provided on the “Materials and methods” paragraph of all works submitted to “MLTJ”.

The submitted manuscripts must comply with the policies of MLTJ. In case of need, the guidelines based on the Committee on Publication Ethics (COPE) on good publication can be consulted.

HUMAN RIGHTS

The study must be conducted in accordance with the ethical standards established in the Declaration of Helsinki of 1946 (World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medicalresearch involving human subjects. JAMA 2013 Nov 27;310(20):2191-4. Doi: 10.1001/jama.2013.281053).

Authors must guarantee that the enrolled participants (or who stands in for – e.g. legal guardians, next of kin in case of death, animal owner) signed an informed consent and that are aware they will be part of a scientific publication.

Patients’ names and unnecessary references to personal aspects (e.g., occupation, residence) or sensitive data (e.g., political preference, etc.) that could reveal the identity of a patient must be omitted from the text and iconographic materials.

ANIMALS RIGHTS

When undertaking animal investigations, the study must have been conducted in accordance with the International Guiding Principles for Biomedical Research Involving Animals for the use of laboratory animals and with local/national guidelines approved by the appropriate committee. The respect of the recommendations must be explicitly stated in the manuscript.

Studies conducted using anaesthesia or euthanasia, in a way incompatible with the commonly accepted norms of veterinary best practice, will not be taken into consideration (see AVMA guidelines for more information).

If a manuscript has been submitted from a country where there is no ethics committee or institutional review board, authors should explain how the study adhered to the World Medical Association Declaration of Helsinki: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

MISCONDUCT/PLAGIARISM

Authors should declare any potentially overlapping publications on submission. Any overlapping publications explicitly identified should be cited.

In case of doubt, the Editors shall require explanations and the full access to the used documents, such as the signed consent forms. The Editors can also proceed with an independent revision of the manuscript to ascertain if the manuscript meets the ethical standards. If any problem emerges, the authors and the institution where the study was conducted will be consulted and updated about the results of such review. The manuscripts could be rejected in case of serious misconduct.

Furthermore, in case of serious proven misconduct, all authors of the indict article shall be banned from future publication in MLTJ.

Each manuscript submitted to MLTJ is peer reviewed and scrutinised using CrossCheck software for evidence of plagiarism (this involves multiple submission, self-plagiarism, etc.). However, a fraudulent article or an article previously published elsewhere could be improperly published. In this case, the article will be retracted. Readers will be informed with a notification on the journal web site (www.mltj.online), and the authors’ institution will be contacted by Editors and/or the Publisher. In case of publication on indexing systems, every appropriate step to identify the fraudulent article will be undertaken, including adding the word “Retraction” in the title.

Data falsification and fabrication

Data falsification means to manipulate data, images, not convenient results, with the intention of giving a false impression, for example increasing the scientific quality of the study.

Any doubt regarding data integrity will be referred to the Editor. The Editor may request the data for inspection or verification. If the original data cannot be provided, the manuscript will be rejected or retracted, depending on the cases.

AUTHORSHIP

The corresponding author is responsible for all the information reported into the manuscript, from the list of the authors (to prevent ghost/gift-guest authorship) to the availability of data.

The corresponding author should gain consent by all co-authors for the submission of the manuscript. Not gaining consent from each author for submission could lead to involuntary misconduct in the form of duplicate submission (see “Misconduct/Plagiarism” paragraph above).

The involvement of scientific (medical) writers or anyone else who helped with the preparation of the manuscript content should be acknowledged, along with their source of funding.

For more information visit ICMJE’s webpage: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html

MANIPULATION OF IMAGES

MLTJ strives to avoid misrepresentation of the data collected. Images cannot be modified (enhancing, obscuring, moving, removing or introducing features) to change the overall appearance or appearance of any specific feature.

Adjustments of brightness and contrast or colour balance are acceptable, but must be applied to the entire image and as long as they do not obscure, eliminate, or misrepresent any information present in the original.

Images collected at different times or from different locations or from different parts of the same gel or from different gels should not be combined into a single image, unless specified. In this case, the edges must be clearly delimited (e.g., dividing lines) in the figure and described in the legend.

Please visit the following websites:

for greater details.

BIOSAFETY AND BIOSECURITY

Every article submitted to MLTJ must be compliant with relevant institutional biosafety and biosecurity protocols/national or international recommendations.

STANDARDS FOR RESEARCH

MLTJ welcomes in vitro/in vivo manuscripts for submission which meet the following clinical research criteria:

adequately controlled (describe the comparison: placebo or conventional medicine use);
blinded (where appropriate);
randomised;
with sufficient statistical power depending on the sample size.

SUGGESTED GUIDELINES TO FOLLOW ACCORDING TO THE TYPE OF ARTICLE

MLTJ suggests to check the following guidelines when writing the manuscript:

Randomized controlled trials (follow CONSORT)
Systematic reviews and meta-analyses (PRISMA)
Observational studies (STROBE)
Diagnostic/prognostic studies (STARD and TRIPOD)
Pre-clinical animal studies (ARRIVE)

TRIAL REGISTRATION

MLTJ supports registration of clinical trials. Registration number should be included as the last line of the manuscript abstract.

MLTJ adheres to the World Health Organization (WHO) definition of a clinical trial, which is “any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes”. This definition includes phase I to IV trials. Health-related interventions are defined as “any intervention used to modify a biomedical or health-related outcome” and health-related outcomes as “any biomedical or health-related measures obtained in patients or participants”. Authors could consult the ICMJE FAQs if they are unsure whether their trial needs to be registered.

Suitable publicly available registries are listed on the ICMJE website as well as the primary registries that participate in the WHO International Clinical Trials Registry Platform.

Examples of public Clinical Trials Registry are:

MLTJ encourages the publication of study protocols: it reduces the risk of non-publication of research findings and facilitates methodological discussion. If the study protocol for a trial has been published, it should be cited in the manuscript.

For clinical trials that have not been registered prospectively, MLTJ encourages retrospective registration.

MLTJ will consider manuscripts describing retrospectively registered studies.

Protocol of randomized controlled trials should follow the CONSORT extension for abstracts and the CONSORT guidelines.

REGISTRATION OF SYSTEMATIC REVIEWS

MLTJ supports the prospective registration of systematic reviews and encourages authors to register their systematic reviews in a suitable registry (such as PROSPERO). Authors who have registered their systematic review should include the registration number as the last line of the manuscript abstract.

RESEARCH DATA POLICY

MLTJ strongly encourages that all datasets on which the conclusions of the article rely should be available to readers upon request. The authors should provide a link to the repository used to archive the data supporting the results. Authors are required to provide a data availability statement reporting on the availability or the absence of shared data.

Submission of a manuscript to MLTJ implies that any unique materials described in the manuscript will be freely available to scientists wishing to use them for non-commercial purposes.

For datasets containing clinical data, authors have ethical and legal responsibilities to protect the privacy and the identity of participants. Participants, once recruited, should sign an informed consent for the publication of the dataset. In case of impossibility, authors must demonstrate the publication of data does not compromise the legal rights of participants. Authors must include in their manuscript whether informed consent was obtained for publication of patient data. If informed consent was not obtained, authors must state the reason.

Third part data

If a third part is consulted to generate or analyse part or all of the data presented in the study, this aspect should be clearly stated into “Materials and methods” section. If it is not possible, the unavailability should be clearly stated.

PHARMACEUTICAL COMPANIES

If a study has been financed by pharmaceutical companies, the Ethics standards of the Journal, the Author Guidelines and the good publication practice must be followed (read also the updating https://www.ismpp.org/gpp-2022).

CONFLICT OF INTERESTS

A conflict of interest can be financial or non-financial. It rises when the authors’ interpretation/presentation of data/information may be influenced, or just perceived as influenced, by personal or financial relationship with other organizations. Authors must disclose any financial competing interests and any non-financial competing interests.

A Conflict of Interests disclosure form must be signed by each author and the presence or the absence of conflict of interests must be clearly stated in the title page (see “Author Guidelines” – “Before Submission”). The Conflict of Interests document intends to specify all financial, personal and professional relationships that could be a conflict of interest or could be perceived as a conflict of interest or could affect the study of the author.

Once the issue will be online, all the declarations will appear after the Acknowledgements section (if present) of each article, in a specific paragraph entitled Conflict of interests. If authors declare no conflict of interests, a default sentence will be report: “The authors declare that they have no conflict of interests”. In case of conflicts, an ad-hoc sentence will be prepared.

The authors will be held responsible for any false declarations or noncompliance with the instructions specified above.

The editorial office reserves the right to reject any manuscript that does not conform to the above-described instructions.

PUBLISHER POLICY

Edra designs advanced solutions that reshape the value chain and contribute to tangibly building the future of the Healthcare system. Edra designs new processes, new platforms, new systems to improve the knowledge and the decisions of patients, clinics, pharmacists, decision makers: levers that can drive the evolution of the system, guaranteeing better dialogue, the prompt availability of essential information and effective processes.

It provides custom solutions and services thanks to a dedicated team of professionals that operate in the following areas: publications & advisory boards, digital solutions, residential, on-the-job and online training, communication & pr.

For further information visit www.edraspa.it and to explore the scientific publications published by Edra visit https://www.edraspa.it/competenze/pubblicazioni/

Please, take into consideration that Edra webiste is in Italian language.

Sharing the same ethical value, Edra S.p.A publishes M.L.T.J. on behalf of I.S.Mu.L.T. Italian Society of Muscles, Ligaments and Tendons.

Edra SpA applies rigorous Ethical standards to guarantee high-quality scientific publications to respect the willingness of the I.S.Mu.L.T.

The submitted manuscripts must comply with the policies of M.L.T.J. In case of need, the guidelines based on the Committee on Publication Ethics (COPE) on good publication practice can be consulted.

Edra supports the COPE Core Practices, along with I.S.Mu.L.T, specifically in case of Complaints and Appeals. For Authorship criteria or Clinical trial registration or Information about Conflict of interests, the Publisher endorses the recommendations of the International Committee of Medical Journal Editors (http://www.icmje.org/).

MANAGEMENT OF SUBMISSIONS

Edra entrusts to Editorial Manager® by Aries Systems Corporation to the submission of the manuscripts, where one of the authors listed – usually the Corresponding author – is called to upload the manuscript in behalf of all the authors. The submitted manuscript must be original and must not have been published nor submitted for publication elsewhere.

When a new submission is received, the publisher’s office conducts an initial check of format and completeness of authors to assess if the authors followed the Instructions for authors. In case of discrepancies, the Editorial Office send back the manuscript with detailed information about the errors and the required modifications.

Involved parts

All submitted manuscripts are confidential documents. No information will be shared without the written permission of the author(s).

During the revision process, the following people may access to manuscripts:

Editors;
Members of Editorial Office;
Reviewers;
Authors.

In case of serious misconduct research, the Journal reserves the right to involve third parties.

Article withdrawal

Edra admits articles withdrawal upon request from the authors, in case manuscript has not received a final decision yet.

In case of acceptance and authors’ withdrawal willingness:

If a doi has not already been associated to the article, the article will be archived without publication.
If the article is ready to be published in a specific volume ad issue, the request of withdrawal will be rejected, and the article published with a retraction note.

CONFLICT OF INTERESTS

Authors are called to sign a conflict of interest form. All the authors should sign: in case of difficulties in gathering all the signatures and absence of conflict of interests, only the corresponding authors can sign it in behalf of all the authors.

A conflict of interest may exist when an author or the author’s institution has a financial or other relationship with other people or organizations within three (3) years of beginning the work submitted that could inappropriately influence (bias) their work. Financial relationships are easily identifiable, but conflicts can also occur because of personal relationships, academic competition, or intellectual rivalry. A conflict can be actual or potential and full disclosure to the Journal is the safest course. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

The Conflict of interest can be:

□ Employment

□ Research funding (including funds received or pending for research in which one of more authors were the principal investigator, collaborator, or consultant)

□ Other Research Support (including receipt of drugs, supplies, equipment, or other in-kind support)

□ Honoraria (icluding fees received for speaking during symposia and other meetings or occasions)

□ Expert Witness (serving as an expert witness, consultant or otherwise providing a deposition, testimony, or other information, analysis or document for a lawsuit, government agency proceeding, grand jury, or other legal proceeding, even if the case did not go to trial)

□ Ownership Interest (stocks or stock options; partnership, membership, any rights in any patent or other intellectual property)

□ Other

□ None

ETHICAL APPROVAL

Manuscripts that report the results of research conducted on human subjects should include a declaration that the study protocol was approved by the competent Ethics Committee, that the study was conducted in accordance with the ethical standards established in the Declaration of Helsinki of 1946, and that informed consent was obtained from all participants before enrolment in the study.

If experiments have been conducted on animals, the study must have been conducted in accordance with the International Guiding Principles for Biomedical Research Involving Animals guidelines recommended by the World Health Organization (WHO) for the use of laboratory animals, and such adherence must be explicitly stated in the manuscript.

If a paper has been submitted from a country where there is no ethics committee, institutional review board, or similar review and approval, authors should explain how the study adhered to the World Medical Association Declaration of Helsinki: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

COPYRIGHT AND PERMISSIONS

All material published by Edra is protected by “I.S.Mu.L.T copyright, including the right to provide the Article in electronic and online forms and systems. With respect to supplemental data that the authors make accessible through a link in the Article, they hereby grant a non-exclusive license for such linking.

The authors retain or are hereby granted the Rights:

in patents, trademarks or other intellectual property rights;
to use the Preprint or Accepted Author Manuscript for:
- Personal Use: use by an author in the author’s classroom teaching ‒ including distribution of copies, paper or electronic ‒, distribution of copies to research colleagues for their personal use, use in a subsequent compilation of the author’s works, inclusion in a thesis or dissertation, preparation of other derivative works such as extending the article to book-length form, or otherwise using or re-using portions or excerpts in other works ‒ with full acknowledgment of the original publication of the article;
- Internal Institutional Use: use by the author’s institution for classroom teaching at the institution including distribution of copies, paper or electronic, and use in course packs and courseware programs. For authors employed by companies, the use by that company for internal training purposes;
- Scholarly Purposes: voluntary posting of Articles or Preprints by an author on open Web sites operated by the author or the author’s institution for scholarly purposes, as determined by the author, or on preprint servers, but not for Commercial Use or Systematic Distribution. The author should include the appropriate bibliographic citation when posting.
the right to use the Published Journal Articles for personal use and internal institutional use.

In each case Commercial Use or Systematic Distribution are excluded.

Commercial Use means the use or posting of articles for commercial gain or to substitute for the services provided directly by the journal including:

the posting by companies of their employee-authored works for use by customers of such companies (e.g. pharmaceutical companies and physician-prescribers);
commercial exploitation such as directly associating advertising with such posting or the charging of fees for document delivery or access.

Systematic distribution means Policies or other mechanisms designed to aggregate and openly disseminate manuscripts or articles, or to substitute for journal-provided services, including:

the systematic distribution to others via e-mail lists or list servers (to parties other than known colleagues), whether for a fee or for free;
the posting of links to sponsored articles by commercial third parties including pharmaceutical companies;
institutional, funding body or government manuscript posting policies or mandates that aim to aggregate and openly distribute the accepted, peer reviewed manuscripts or published journal articles authored by its researchers or funded researchers;
subject repositories that aim to aggregate and openly distribute accepted peer-reviewed manuscripts or published journal articles authored by researchers in specific subject areas.

Each individual interested in reproducing tables, figures or intended to cite entirely or a part of the published articles contacts editorialoffice@mltj.online to request the permission to reproduce our content. Usually, the Editorial Office releases the permission if an appropriate citation to the article and Journal is guaranteed.

ARTICLE PROCESSING CHARGES

Although M.L.T.J. publishes articles under an open access model, for the time being it does not impose any fees or Author Publication Charges (APC).

There are no submission charges, no charges for rejected/accepted articles, no revision charges, no charges based on the length of a manuscript or type of a manuscript, no supplement charges for the presence of figures/tables or supplementary files, and no fees to publication. The process, from submission to publication, is entirely free.

ADVERTISING POLICIES

If a study has been financed by pharmaceutical companies, the Ethics standards of the Journal, the Author Guidelines and the good publication practice (https://www.ismpp.org/gpp3) must be followed (read also the updating https://www.ismpp.org/gpp-2022).

Edra, along with I.S.Mu.L.T., can refuse to accept sponsorship from any commercial enterprise. Advertised articles undergo to the same treatment of non-sponsored articles, being processed with peer-review activity and Sponsors or Clients don’t have control over the editorial decision.

Sponsorship for the Journal

M.L.T.J. does not receive any external funding for its maintenance and development. All the expenses for maintenance and development of the Journal are covered by I.S.Mu.L.T.

APPEALS AND COMPLAINTS

If the authors wish to ask the Editor or Editorial Board to reconsider a rejection of a manuscript, they are allowed to do so. They have to contact the Editorial Office providing a formal letter of appeal, which will be forwarded to the Editor in Chief or a Deputy Editor. Only one appeal is permitted for each manuscript.

The authors can appeal in the case they can demonstrate the existence of an error which took place during revision process or if some fundamental additional data can be provided. We invite you to read ETHICS APPROVAL FOR PAPERS SUBMITTED TO “MUSCLES, LIGAMENTS AND TENDONS JOURNAL” – MLTJ for further information.

PRIVACY POLICY

We invite you to read Privacy – MLTJ for further information about privacy policies.

SUBSCRIBERS

If you subscribe to our newsletter, you receive a notification email when a ordinary/special issue is published. Every newsletter contains an unsubscribe link in its footer.

PUBLICATION OF CORRECTIONS

The Journal offers to publish correction just in case the errors could affect the interpretation of the study.

PLAGIARISM

Information about Plagiarism and Self-plagiarism is available at ETHICS APPROVAL FOR PAPERS SUBMITTED TO “MUSCLES, LIGAMENTS AND TENDONS JOURNAL” – MLTJ. Authors are required to perform plagiarism screening, using tools such as CrossCheck by iThenticate or similar, before submission.

Early
view

Back
issues

Submit
your paper

Aims
& scope